Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 339	$ 436	$ 478	$ 601
Operating expenses:
Research and development (including amounts with related parties)	53,800	33,005	94,928	60,379
Selling, general and administrative (including amounts with related parties)	32,445	18,347	77,720	27,840
Total operating expenses	86,245	51,352	172,648	88,219
Loss from operations	(85,906)	(50,916)	(172,170)	(87,618)
Other (expense) income:
Interest and investment (loss) income, net	(177)	986	8,767	1,064
Interest expense (including amounts with related parties)	(3,577)	(2,123)	(6,745)	(4,012)
Other income, net (including amounts with related parties)	277	81	290	1,185
Total other (expense) income	(3,477)	(1,056)	2,312	(1,763)
Loss before income taxes and noncontrolling interests	(89,383)	(51,972)	(169,858)	(89,381)
Income tax expense	(2)	(45)	(8)	(63)
Net loss	(89,385)	(52,017)	(169,866)	(89,444)
Net loss attributable to noncontrolling interests, net of tax	(1,097)	(578)	(1,964)	(967)
Net loss attributable to ImmunityBio common stockholders	$ (88,288)	$ (51,439)	$ (167,902)	$ (88,477)
Net loss per ImmunityBio common share – basic and diluted	$ (0.23)	$ (0.14)	$ (0.44)	$ (0.24)
Weighted-average number of common shares used in computing net loss per share – basic and diluted	384,820,486	372,286,278	383,939,031	372,137,752